Cerebrolysin Pharmacology and Side Effects
Cerebrolysin is a porcine brain-derived neuropeptide preparation that mimics endogenous neurotrophic factors, and while it demonstrates a favorable safety profile with generally mild and transient adverse events, the most common side effects include dizziness/vertigo, agitation, and feeling hot.
Pharmacology
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue 1. Its pharmacodynamic properties parallel those of endogenous neurotrophic factors, allowing it to cross the blood-brain barrier and exert multi-target neuroprotective effects 2, 3.
Mechanism of Action
The drug operates through several complementary pathways 3, 4:
- Neuroprotection: Stabilizes cellular structural integrity by inhibiting calpain and reducing apoptotic cell death
- Neurotrophic effects: Promotes neurogenesis in the dentate gyrus and subventricular zone
- Neuroplasticity: Increases synaptic density and restores neuronal cytoarchitecture
- Anti-amyloid effects: Decreases β-amyloid deposition and reduces tau phosphorylation by regulating glycogen synthase kinase-3β
- BBB repair: Restores blood-brain barrier integrity and improves cerebral perfusion 4
Side Effects Profile
Common Adverse Events
The most frequently reported adverse events are mild and transient 5:
- Dizziness or vertigo (most common)
- Agitation
- Feeling hot/flushing
Serious Adverse Events
Moderate-certainty evidence from controlled trials indicates that Cerebrolysin probably results in little to no difference in fatal serious adverse events (RR 0.90,95% CI 0.59 to 1.38) 6. However, there is a potential increase in non-fatal serious adverse events (RR 2.39,95% CI 1.10 to 5.23), particularly with the 30 mL for 10 days dosing schedule (cumulative dose 300 mL), where the increase was more prominent (RR 2.87,95% CI 1.24 to 6.69) 6.
Overall Safety Assessment
In controlled clinical trials, the incidence of adverse events was similar between Cerebrolysin-treated and placebo-treated groups 5. The drug was not associated with major changes in vital signs or laboratory parameters 5.
Drug Interactions and Combination Safety
Cerebrolysin appears safe when used in combination with:
- Recombinant tissue-type plasminogen activator (tPA) 7, 5
- Cholinesterase inhibitors (donepezil, rivastigmine) 5
- Mechanical thrombectomy (with reduced symptomatic intracranial hemorrhage: RR 0.12,95% CI 0.03-0.48) 8
Clinical Context
While small studies suggested potential benefits in acute ischemic stroke 9, 10, moderate-certainty evidence from systematic reviews indicates that Cerebrolysin probably has no beneficial effect on preventing all-cause death in acute ischemic stroke (RR 0.96,95% CI 0.65 to 1.41) 6. The drug shows more promise in moderate-to-severe stroke populations and in dementia management 2, 11, 12.
Contraindications and Precautions
Per FDA labeling 1:
- Keep out of reach of children
- Discontinue use if symptoms persist, worsen, or new symptoms occur
- Consult healthcare professional if pregnant or breastfeeding
- Seek immediate medical attention for overdose